GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosesesimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsGUANGZHOU, China - Bio-Thera Solutions (688177.S H ), a commercial-stage biopharmaceutical company developinginnovative therapies and biosesesimilars, announced that its partner, Biogen Inc.(Nasdaq: BIIB) officially launched TOFIDENCE (tocilizumab-bavi) intravenousformulation, a biosesesimilar monoclonal an...
Guangzhou, China -- Bio-Thera Solutions(688177:SH), a commercial-stage biopharmaceutical company developing a pipelineof innovative therapies and biosesesimilars, today announced receiving INDclearance from the US FDA for a phase II Study for BAT8006, an innovative AntibodyDrug Conjugate (ADC) targeting...
GUANGZHOU, China and San José, Costa Rica- Bio-Thera Solutions, a commercial-stagebiopharmaceutical company developing innovative therapies and biosesesimilars, andSteinCares, one of Latin America’s leading specialty healthcare companies,announced today a new licensing agreement for two biosesesimilars u...
